Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
Oh et al.
, Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in..
, Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577
Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients.
risk of death, 1.0% lower, OR 0.99, p = 0.95, adjusted per study, multivariable, RR approximated with OR.
risk of case, 12.0% lower, RR 0.88, p = 0.04, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oh et al., 17 Jun 2021, retrospective, database analysis, South Korea, peer-reviewed, 4 authors.
Abstract: Original Article
Yonsei Med J 2021 Jul;62(7):577-583
pISSN: 0513-5796 · eISSN: 1976-2437
Incidence and Mortality Associated with Cardiovascular
Medication among Hypertensive COVID-19 Patients
in South Korea
Tak Kyu Oh1*, Hyoung-Won Cho2*, Jung-Won Suh2, and In-Ae Song1
Departments of 1Anesthesiology and Pain Medicine and 2Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital,
Purpose: We aimed to investigate whether the use of cardiovascular drugs in coronavirus disease 2019 (COVID-19) patients with
hypertension as a comorbidity has a significant effect on the incidence and associated mortality rate of COVID-19.
Materials and Methods: Data covering the period between January 1, 2020 and June 4, 2020 were extracted from The National
Health Insurance Service-COVID-19 (NHIS-COVID-19) database in South Korea and analyzed as a population-based cohort study.
Results: A total of 101657 hypertensive adults aged 20 years or older were included for final analysis. Among them, 1889 patients
(1.9%) were diagnosed with COVID-19 between January 1, 2020 and June 4, 2020, and hospital mortality occurred in 193 patients
(10.2%). In a multivariable model, the use of beta-blockers was associated with an 18% lower incidence of COVID-19 [odds ratio
(OR): 0.82, 95% confidence interval (CI): 0.69–0.98; p=0.029]. Among 1889 hypertensive patients diagnosed with COVID-19, the
use of a calcium channel blocker (CCB) was associated with a 42% lower hospital mortality rate (OR: 0.58, 95% CI: 0.38–0.89;
p=0.012). The use of other cardiovascular drugs was not associated with the incidence of COVID-19 or hospital mortality rate
among COVID-19 patients. Similar results were observed in all 328374 adults in the NHIS-COVID-19 database, irrespective of the
presence of hypertension.
Conclusion: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensive patients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findings
were also applied to the general adult population, regardless of hypertension.
Key Words: Hypertension, aspirin, clopidogrel, viruses, cohort studies
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.